This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reynaud, R. Articles by Barlier, A. Search for Related Content PubMed PubMed Citation Articles by Reynaud, R. Articles by Barlier, A. Related Collections Neuroendocrinology and Pituitary Pediatric Endocrinology

Genetic Screening of Combined Pituitary Hormone Deficiency: Experience in 195 Patients

Departments of Pediatrics (R.R.) and Endocrinology (M.G., A.S., S.V.-K., T.B., A.B.), Centre Hospitalo Universitaire Timone, 13385 Marseille Cedex 5, France; Laboratory of Biochemistry and Molecular Biology (A.S., A.E., A.B.), Centre Hospitalo-Universitaire Conception, 13385 Marseille Cedex 5, France; and Laboratory Interactions Cellulaires Neuroendocriniennes (R.R., A.S., A.E., T.B., A.B.), Centre National de la Recherche Scientifique Unité Mixte de Recherche 6544, Institut Fédératif Jean Roche, Faculté de Médecine, Université de la Méditerranée, 13284 Marseille Cedex 7, France

Address all correspondence and requests for reprints to: Dr. Anne Barlier, Laboratoire de Biochimie et Biologie Moléculaire, Hôpital de la Conception, 13385 Marseille Cedex 5, France. E-mail: barlier.anne{at}ap-hm.fr.

Context: Mutations in transcription factors result in combined pituitary hormone deficiency (CPHD).

Objective: A genetic screening strategy, based on endocrine and neuroradiological phenotype according to published knowledge, was applied to establish the prevalence of gene defects in each category of patients and provide a useful framework for clinicians to determine the genetic etiology and recurrence risks for individuals and families.

Design: One hundred ninety-five CPHD patients from the international GENHYPOPIT network were studied, according to their phenotype, for POU1F1, PROP1, LHX3, LHX4, and HESX1.

Patients: Patients selected had two pituitary hormone deficiencies or at least one deficiency with intracerebral malformations.

Results: Total prevalence of mutations was 13.3 and 52.4% in 20 patients with familial CPHD history. No mutation of HESX1 was observed in 16 patients harboring septooptic dysplasia. A mutation of LHX4 gene, previously reported, was found in one familial case from 39 patients bearing pituitary stalk interruption syndrome. In 109 patients without extrapituitary abnormalities, 20 had PROP1 mutations, including eight patients with a family history of CPHD. Among 20 patients without pituitary stalk interruption syndrome, no LHX3 gene defect was found, even with a neck rotation deficit. One POU1F1 gene defect was found in one patient presenting the rare postpubertal association of thyrotroph (TSH deficiency) and somatotroph (GH deficiency) deficits.

Conclusions: Mutation of PROP1 gene remains the first to be looked for, and POU1F1 mutations should be sought in GH deficiency and TSH deficiency postpubertal population without extrapituitary malformations. Identification of gene defects allows early treatment of any deficit and prevention of their potentially fatal consequences. Genotyping appears highly beneficial at an individual and familial level.

This article has been cited by other articles:

				F. Castinetti, A. Saveanu, R. Reynaud, M. H. Quentien, A. Buffin, R. Brauner, N. Kaffel, F. Albarel, A. M. Guedj, M. El Kholy, et al. A Novel Dysfunctional LHX4 Mutation with High Phenotypical Variability in Patients with Hypopituitarism J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2790 - 2799. [Abstract] [Full Text] [PDF]